Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  BioPorto A/S    BIOPOR   DK0011048619

BIOPORTO A/S (BIOPOR)

Delayed Quote. Delayed  - 08/26 04:41:50 pm
2.24 DKK   -0.44%
08/08 BIOPORTO A/S : Jan Kuhlmann Andersen new COO in BioPorto A/S - resig..
08/04 BIOPORTO A/S : Interim report, first half of 2016
07/06 BIOPORTO A/S : BioPortos NGAL Exclusion patent is ruled invalid by t..
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
08/22/2016 08/23/2016 08/24/2016 08/25/2016 08/26/2016 Date
2.22(c) 2.22(c) 2.23(c) 2.25(c) 2.24(c) Last
495 156 387 011 131 613 193 788 240 802 Volume
+1.83% 0.00% +0.45% +0.90% -0.44% Change
More quotes
Company
BioPorto A/S is an in-vitro diagnostics company.It provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies.The company focuses on the diagnosis of obesity, diabetes, primary immune deficiency, and kidney injury.Its products include The NGAL... 
Sector
Pharmaceuticals
Calendar
11/03Earnings Release
More about the company
Latest news on BIOPORTO A/S
08/08 BIOPORTO A/S : Jan Kuhlmann Andersen new COO in BioPorto A/S - resigns from the ..
08/04 BIOPORTO A/S : Interim report, first half of 2016
07/06 BIOPORTO A/S : BioPortos NGAL Exclusion patent is ruled invalid by the EPO BioPo..
07/05 BIOPORTO A/S : NGAL Exclusion patent is ruled invalid by the EPO – to appe..
07/04 BIOPORTO A/S : decides to reapply for FDA approval of The NGAL TestTM
06/07 BIOPORTO A/S : Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Fo..
06/06 Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Following FDA'..
06/06 BIOPORTO A/S : Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Fo..
05/28 BIOPORTO A/S : The FDA rejects application for the registration og The NGAL Test..
05/19 BIOPORTO A/S : BioPortos NGAL Forms patent is upheld after EPO ruling
More news
Sector news : Diagnostic & Testing Substances Manufacturers
08/27 Stada shareholder AOC pushes through board reshuffle
08/27 ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Diagnostic & Testing Substances Manufacturers
Advertisement
Chart BIOPORTO A/S
Duration : Period :
BioPorto A/S Technical Analysis Chart | BIOPOR | DK0011048619 | 4-Traders
Full-screen chart
Technical analysis trends BIOPORTO A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Managers
NameTitle
Peter Mørch Eriksen CEO & Investor Relations Contact
Thomas Magnussen Chairman
Michael Pålsson Chief Operating Officer
Jakob Brix Christensen Chief Financial Officer
Torben A. Nielsen Vice Chairman
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOPORTO A/S-53.53%0
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-12.84%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-10.83%210 234
ASTRAZENECA PLC7.33%173 797
More Results